Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Localized scleroderma (morphea)].

Waafa Bono1, Nicolas Dupin

  • 1Service de Médecine Interne, Hôpital Cochin, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, AP-HP et Université Paris-Descartes, Faculté de Médecine Paris-Descartes, Paris.

Presse Medicale (Paris, France : 1983)
|December 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolated perianal hypertrophic lichen planus in men.

Clinical and experimental dermatology·2026
Same author

Management and predictors of ICU admission in DRESS: A multicentre retrospective cohort study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Genital ulcer associated with an uncommon viral infection.

Clinical and experimental dermatology·2026
Same author

Incidence and Mortality of Mucous Membrane Pemphigoid in France.

The British journal of dermatology·2026
Same author

Successful treatment of multicentric reticulohistiocytosis with JAK inhibitor: a case series.

RMD open·2026
Same author

18F-fluorodeoxyglucose PET/CT uptake characteristics in immune checkpoint inhibitor-induced polymyalgia rheumatica compared to idiopathic polymyalgia rheumatica.

Rheumatology (Oxford, England)·2026
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Localized scleroderma (morphea) is a skin condition with a good prognosis, especially superficial forms which resolve within 3 years. Treatment depends on lesion severity and extent.

Area of Science:

  • Dermatology
  • Rheumatology
  • Immunology

Background:

  • Localized scleroderma, or morphea, is a distinct skin-only sclerotic condition.
  • Its presentation varies based on lesion extent, arrangement, and depth.
  • Morphea is significantly more common than systemic sclerosis, with superficial types typically resolving within three years.

Purpose of the Study:

  • To define localized scleroderma (morphea) and its clinical variations.
  • To discuss the prevalence, prognosis, and potential systemic involvement of morphea.
  • To outline current treatment strategies based on disease characteristics.

Main Methods:

  • Clinical observation and classification of morphea based on lesion characteristics.
  • Review of diagnostic criteria and prognostic indicators.

Related Experiment Videos

  • Evaluation of treatment modalities for different morphea presentations.

    • Main Results:

    • Plaque morphea is the most common form.
    • Extensive or linear morphea, particularly in children, can lead to severe functional or aesthetic complications.
    • No specific immunological markers or causative agents are identified for morphea pathogenesis.

    Conclusions:

    • Morphea management requires individualized treatment plans.
    • Superficial lesions may be treated with topical corticosteroids.
    • Systemic therapy, such as methotrexate, is considered for severe or extensive morphea forms with complication risks.